Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporatedverified

VRTX

Price:

$466.1

Market Cap:

$118.39B

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clin...[Read more]

Industry

Biotechnology

IPO Date

1991-07-24

Stock Exchange

NASDAQ

Ticker

VRTX

The Enterprise Value as of March 2026 (TTM) for Vertex Pharmaceuticals Incorporated (VRTX) is 117.18B

According to Vertex Pharmaceuticals Incorporated’s latest financial reports and current stock price. The company's current Enterprise Value is 117.18B. This represents a change of 5.75% compared to the average of 110.82B of the last 4 quarters.

Vertex Pharmaceuticals Incorporated (VRTX) Historical Enterprise Value (quarterly & annually)

How has VRTX Enterprise Value performed in the past?

The mean historical Enterprise Value of Vertex Pharmaceuticals Incorporated over the last ten years is 63.00B. The current 117.18B Enterprise Value has changed 18.50% with respect to the historical average. Over the past ten years (40 quarters), VRTX's Enterprise Value was at its highest in in the March 2025 quarter at 121.52B. The Enterprise Value was at its lowest in in the December 2016 quarter at 17.74B.

Quarterly (TTM)
Annual

Average

63.00B

Median

55.06B

Minimum

17.60B

Maximum

114.72B

Vertex Pharmaceuticals Incorporated (VRTX) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Vertex Pharmaceuticals Incorporated Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 105.85%

Maximum Annual Enterprise Value = 114.72B

Minimum Annual Increase = -42.13%

Minimum Annual Enterprise Value = 17.60B

Quarterly (TTM)
Annual
YearEnterprise ValueChange
2025114.72B13.72%
2024100.88B5.86%
202395.29B48.08%
202264.35B26.77%
202150.76B-9.92%
202056.35B4.82%
201953.76B34.15%
201840.08B10.60%
201736.23B105.85%
201617.60B-42.13%

Vertex Pharmaceuticals Incorporated (VRTX) Average Enterprise Value

How has VRTX Enterprise Value performed in the past?

The current Enterprise Value of Vertex Pharmaceuticals Incorporated (VRTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

103.63B

5-year avg

85.20B

10-year avg

63.00B

Vertex Pharmaceuticals Incorporated (VRTX) Enterprise Value vs. Peers

How is VRTX’s Enterprise Value compared to its peers?

Vertex Pharmaceuticals Incorporated’s Enterprise Value is less than McKesson Corporation (122.09B), less than HCA Healthcare, Inc. (166.60B), less than Medtronic plc (140.21B), greater than Sanofi (106.53B), greater than Regeneron Pharmaceuticals, Inc. (78.23B), greater than GSK plc (95.50B), less than Bristol-Myers Squibb Company (158.53B), greater than argenx SE (40.47B), less than CVS Health Corporation (181.57B), less than Stryker Corporation (144.62B),

CompanyEnterprise ValueMarket cap
122.09B$116.42B
166.60B$117.44B
140.21B$113.29B
106.53B$106.22B
78.23B$78.64B
95.50B$107.82B
158.53B$121.60B
40.47B$43.52B
181.57B$96.48B
144.62B$133.77B

Build a custom stock screener for Vertex Pharmaceuticals Incorporated (VRTX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Vertex Pharmaceuticals Incorporated using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Vertex Pharmaceuticals Incorporated (VRTX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Vertex Pharmaceuticals Incorporated or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Vertex Pharmaceuticals Incorporated's Enterprise Value?

What is the highest Enterprise Value for Vertex Pharmaceuticals Incorporated (VRTX)?

What is the 3-year average Enterprise Value for Vertex Pharmaceuticals Incorporated (VRTX)?

What is the 5-year average Enterprise Value for Vertex Pharmaceuticals Incorporated (VRTX)?

How does the current Enterprise Value for Vertex Pharmaceuticals Incorporated (VRTX) compare to its historical average?